Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Pacira BioSciences, Inc., the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. The company achieved record-high EXPAREL sales driven by volume growth of 7 percent, marking the strongest fourth quarter performance in three years. Pacira also delivered strong, measurable progress across its business, generating $726 million in revenue and achieving the highest gross margins in the company's history.

Why it matters

Pacira's performance continues to be led by EXPAREL, which is benefitting from expanding reimbursement, growing commercial adoption, and strengthened intellectual property providing protection into the 2040s. The company further extended its commercial reach through strategic collaborations, while advancing clinical programs positioned to deliver a data-rich year. Pacira enters 2026 stronger than ever as it continues to redefine what is possible in innovative non-opioid pain management.

The details

Pacira reported fourth quarter revenues of $196.9 million and full-year revenues of $726.4 million. Fourth quarter GAAP net income was $1.6 million or $0.04 per basic and diluted share, and full-year GAAP net income was $7.0 million or $0.16 per basic and diluted share. The company's fourth quarter adjusted EBITDA was $38.7 million and full-year adjusted EBITDA was $186.5 million. Pacira also repurchased 2.0 million shares of common stock at an average price of $24.94 in the fourth quarter, bringing the full year 2025 total to 5.9 million shares repurchased for $150.0 million.

  • In January 2026, the company announced the appointment of Samit Hirawat, M.D., to its Board of Directors.
  • In January 2026, the company announced an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets.

The players

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company's history. Together, these results clearly validate the impact and promise of our 5x30 strategy.”

— Frank D. Lee, Chief Executive Officer of Pacira BioSciences (Pacira BioSciences)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.